How has been the historical performance of Ipca Labs?

Answer:The historical performance of Ipca Labs shows a consistent growth trajectory in net sales and profits over the years, with net sales reaching 8,939.59 Cr in March 2025, up from 7,705.04 Cr in March 2024 and 6,244.32 Cr in March 2023. The total operating income has mirrored this growth, reflecting an increase to 8,939.59 Cr in March 2025. Operating profit (PBDIT) also demonstrated a positive trend, rising to 1,818.94 Cr in March 2025 from 1,445.93 Cr in March 2024. However, profit after tax saw fluctuations, peaking at 1,148.84 Cr in March 2021 before declining to 787.53 Cr in March 2025. The company's total assets increased significantly to 11,743.63 Cr in March 2025, compared to 11,097.05 Cr in March 2024, indicating robust asset growth. On the liabilities side, total liabilities also rose to 11,743.63 Cr in March 2025, reflecting the company's expanding operations. Cash flow from operating activities improved to 1,321.00 Cr in March 2025, showcasing enhanced operational efficiency.

Breakdown:
Ipca Labs has shown a strong upward trend in net sales, which increased from 5,419.99 Cr in March 2021 to 8,939.59 Cr in March 2025. This growth is accompanied by a rise in total operating income, which reached the same figure of 8,939.59 Cr in March 2025. Operating profit (PBDIT) also increased, peaking at 1,818.94 Cr in March 2025, although profit after tax has fluctuated, dropping from a high of 1,148.84 Cr in March 2021 to 787.53 Cr in March 2025. The company's total assets rose significantly to 11,743.63 Cr in March 2025, reflecting strong growth in both current and non-current assets. Total liabilities matched this growth, also reaching 11,743.63 Cr in March 2025. Furthermore, cash flow from operating activities improved to 1,321.00 Cr in March 2025, indicating a positive trend in cash generation from core operations.